Juvenile idiopathic arthritis is the most frequent rheumatic disease in childhood. Its diagnosis
is still clinical and recently new classification criteria have been proposed. Over
the past twenty years, there have been significant improvement in understanding the
pathogenetic mechanisms leading to the implementation of targeted therapies. Indeed,
the introduction of biological drugs has changed the quality of life of these children,
with a rapid control of the disease activity and a reduction in the complications related
to the disease and to the use of steroids, which is today very limited. The way of evaluating
patients has also changed: joint ultrasound has become a fundamental tool of the
daily practice of the paediatric rheumatologists. This article aims to highlight the new
discoveries that have changed the management and prognosis of patients affected by
juvenile idiopathic arthritis.
Vuoi citare questo contributo?
L'accesso è riservato agli abbonati
alla rivista che si siano registrati.
Per accedere all'articolo in formato full text è necessario inserire username e password.
L'immissione di nuovi contenuti è riservata ai soli utenti registrati